A new treatment to help heal corneal injuries
Official title: A Novel Therapeutic to Promote Corneal Repair
Funded at Microcures, INC. · NIH-11126997 · Data updated 2026-11-12
This study is testing a new treatment to help heal corneal injuries, especially from burns, by speeding up the healing process and reducing inflammation, so patients with these injuries can recover better and faster.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Microcures, INC. NIH-funded |
| Lab location | 1 site (Santa Cruz, United States) |
| Project start | September 30, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $699,975 |
| NIH project number | 4R42EY034791-02 |
| Project ID | NIH-11126997 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from corneal injuries, particularly those resulting from chemical burns or other severe trauma.
✕Less likely to help
Patients with non-corneal eye conditions or those whose corneal injuries are not severe may not receive benefit from this research.
What this research studies
This research focuses on developing a novel therapeutic approach to enhance the healing of corneal injuries, particularly those caused by alkali burns. The treatment aims to expedite the migration of epithelial cells and promote the reinnervation of the cornea, addressing the complications that arise from inflammation. By applying this therapy topically, it seeks to provide a localized and sustained release of active agents that can improve the healing process and reduce the risk of complications. Patients with corneal injuries may benefit from this innovative approach to wound care.
Why it matters
Potential benefit: If successful, this research could significantly improve the healing outcomes for patients with corneal injuries, leading to better visual function and reduced risk of complications.
How similar studies have gone: While there have been advancements in corneal wound care, this specific approach utilizing Fidgetin-like 2 (FL2) is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Microcures, INC.
Santa Cruz, United States Active
Researchers
- Principal investigator: Kramer, Adam Hildyard — Microcures, INC.
- Study coordinator: Kramer, Adam Hildyard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.